EIF2AK3 and gastric cancer: Indeed, our results are similar to those of Liu et al. who reported an up-regulation of pERK in GC cells treated with the mTOR inhibitor everolimus and the reversal of resistance to everolimus by combining it with the MEK inhibitor trametinib32.